| 1 min read
Register for free to listen to this article
Listen with Speechify
0:00
1:00
LONDON-At a share price of $58 or about $15.6 billion total, AstraZeneca strengthened its pipe- and bottom lines with an agreement to acquire MedImmune. The pharma giant is expected to leverage the new assets with its subsidiary Cambridge Antibody Technology to further entrench itself in a global biologics market that has seen strong growth but continues to find its way alongside small-molecule based therapeutics development.
 
"This acquisition represents a transformational step to deliver our biologics strategy sooner than anticipated," says AstraZeneca CEO David Brennan. "MedImmune adds an exciting existing pipeline, including two late-stage products, great expertise in biologic drug development, and state-of-the-art manufacturing facilities."
 
The deal also opens the door for AstraZeneca to the volatile vaccine market. This sector has experienced significant interest in recent months with strong candidates arising in oncology, which is expected to account for more than half of the expected $15 billion market by 2012, according to recent research by Kalorama Information.

About the Author

Related Topics

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

GreenCooling

Thermo Scientific™ Centrifuges with GreenCool Technology

Next-generation natural refrigerant cooling system for centrifuges, offering a lower Global Warming Potential and reduced energy consumption.
Clear sample tubes are shown in a clear tote with red lids in a sample prep robot with a blue and silver industrial lab background.

The crucial role of sample preparation in biotherapy manufacturing

Discover how better sample preparation can unlock improved assay accuracy and analytical results.
A black mosquito is shown on pink human skin against a blurred green backdrop.

Discovering deeper insights into malaria research

Malaria continues to drive urgent research worldwide, with new therapies and tools emerging to combat the parasite’s complex lifecycle and global burden.
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue